XHKG6606
Market cap830mUSD
Mar 27, Last price
14.14HKD
Name
New Horizon Health Ltd
Chart & Performance
P/E
—
P/S
7.93
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
765m
+259.54%
Net income
-80m
L-97.41%
CFO
-413m
L+16.34%
Profile
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2013 and is headquartered in Hangzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||
Revenues | 764,960 259.54% | 212,761 201.50% | |||
Cost of revenue | 928,063 | 516,924 | |||
Unusual Expense (Income) | |||||
NOPBT | (163,103) | (304,163) | |||
NOPBT Margin | |||||
Operating Taxes | 655 | 20,704 | |||
Tax Rate | |||||
NOPAT | (163,758) | (324,867) | |||
Net income | (80,313) -97.41% | (3,106,040) 293.81% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,207 | 1,956,232 | |||
BB yield | -0.02% | -22.42% | |||
| Debt | |||||
Debt current | 19,847 | 90,630 | |||
Long-term debt | 290,131 | 75,746 | |||
Deferred revenue | |||||
Other long-term liabilities | 601 | 1,543 | |||
Net debt | (951,570) | (625,260) | |||
| Cash flow | |||||
Cash from operating activities | (412,538) | (354,594) | |||
CAPEX | (53,838) | (37,088) | |||
Cash from investing activities | 691,960 | (1,187,309) | |||
Cash from financing activities | 75,478 | 1,783,821 | |||
FCF | (434,616) | (538,734) | |||
| Balance | |||||
Cash | 1,340,311 | 1,742,052 | |||
Long term investments | (78,763) | (950,416) | |||
Excess cash | 1,223,300 | 780,998 | |||
Stockholders' equity | (4,297,871) | (4,227,558) | |||
Invested Capital | 6,665,111 | 6,478,698 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 422,929 | 378,499 | |||
Price | 17.60 -23.64% | 23.05 | |||
Market cap | 7,443,550 -14.68% | 8,724,402 | |||
EV | 6,491,980 | 8,158,288 | |||
EBITDA | (136,777) | (284,889) | |||
EV/EBITDA | |||||
Interest | 7,361 | 7,759 | |||
Interest/NOPBT | |||||